946147-64-4

Upstream product

• 946147-63-3 5-bromo-2-iodo-1,3-diisopropylbenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 80058-84-0 4-bromo-2,6-diisopropylaniline 

Downstream Products

• 946147-66-6 2,6-diisopropyl-4-bromophenylacetaldehyde 

Relevant academic research and scientific papers

A potent photoreactive general anesthetic with novel binding site selectivity for GABAA receptors

The pentameric γ-aminobutyric acid type A receptors (GABAARs) are the major inhibitory ligand-gated ion channels in the central nervous system. They mediate diverse physiological functions, mutations in them are associated with mental disorders and they are the target of many drugs such as general anesthetics, anxiolytics and anti–convulsants. The five subunits of synaptic GABAARs are arranged around a central pore in the order β-α-β-α-γ. In the outer third of the transmembrane domain (TMD) drugs may bind to five homologous intersubunit binding sites. Etomidate binds between the pair of β – α subunit interfaces (designated as β+/α–) and R–mTFD-MPAB binds to an α+/β– and an γ+/β– subunit interface (a β– selective ligand). Ligands that bind selectively to other homologous sites have not been characterized. We have synthesized a novel photolabel, (2,6-diisopropyl-4-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl)methanol or pTFD-di-iPr-BnOH). It is a potent general anesthetic that positively modulates agonist and benzodiazepine binding. It enhances GABA–induced currents, shifting the GABA concentration-response curve to lower concentrations. Photolabeling–protection studies show that it has negligible affinity for the etomidate sites and high affinity for only one of the two R–mTFD-MPAB sites. Exploratory site–directed mutagenesis studies confirm the latter conclusions and hint that pTFD-di-iPr-BnOH may bind between the α+/β– and α+/γ– subunits in the TMD, making it an α+ ligand. The latter α+/γ– site has not previously been implicated in ligand binding. Thus, pTFD-di-iPr-BnOH is a promising new photolabel that may open up a new pharmacology for synaptic GABAARs.

Organic electroluminescent materials and devices

Compounds comprising phosphorescent metal complexes comprising cyclometallated imidazo[1,2-f]phenanthridine and diimidazo[1,2-a:1′,2′-c]quinazoline ligands, or isoelectronic or benzannulated analogs thereof, are described. Organic light emitting diode devices comprising these compounds are also described.

METAL COMPLEXES OF CYCLOMETALLATED IMIDAZO[1,2-f]PHENANTHRIDINE AND DIIMIDAZO[1,2-A:1',2'-C]QUINAZOLINE LIGANDS AND ISOELECTRONIC AND BENZANNULATED ANALOGS THEREOF

The present invention refers to-imidazo [1,2-f] the dee trillion which gets torn phenylphenanthridines and [1,2-a:1 ', 2' -c] quinazoline ligands, or its isoelectronic characteristic and or phosphor including analogue relates to compounds including metal complex. Furthermore, the present invention refers to these compounds including relates organic light emitting diode devices. (by machine translation)

Phosphorescent condensed ring carbene metal complexes for use in organic light emitting devices

The invention relates to a compound comprising a phosphorescent metal complex comprising a monoanionic, bidentate ligand; wherein the metal is selected from the group consisting of the non-radioactive metals with atomic numbers greater than 40; and wherein the bidentate ligand comprises a carbene donor and may be linked with other ligands to comprise a tridentate, tetradentate, pentadentate or hexadentate ligand.